By Amy Orciari Herman
Edited by David G. Fairchild, MD, MPH, and Lorenzo Di Francesco, MD, FACP, FHM
The American Society of Hematology has issued new guidelines on managing venous thromboembolism.
Of the 28 recommendations, published in Blood Advances, 3 are classified as “strong”:
- For patients with pulmonary embolism (PE) and hemodynamic compromise, thrombolytic therapy followed by anticoagulation is recommended over anticoagulation alone.
- For those with deep venous thrombosis (DVT) or PE who have finished primary treatment and will continue a vitamin K antagonist for secondary prevention, an INR range of 2.0–3.0 should be used rather than a lower range.
- For patients with recurrent unprovoked DVT or PE, continuing antithrombotic therapy indefinitely is advised rather than stopping anticoagulation after primary treatment.
The “conditional” recommendations include the following:
